SEC Company Response from Bone Biologics Corp (BBLG, BBLGW) (CIK 0001419554) (BBLG) — Aug 9, 2016
Bone Biologics Corp (BBLG, BBLGW) (CIK 0001419554)
Date: Aug. 9, 2016 · CIK: 0001419554 · Accession: 0001493152-16-012102
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-212892
Letter
BONE BIOLOGICS CORPORATION
321 cOLUMBUS aVENUE
BOSTON, MASSACHUSETTS 02116
August 8, 2016
VIA EDGAR
Securities and Exchange Commission
F Street, N.E.
Washington, D.C. 20549-6010
Re: Bone Biologics Corporation; Registration Statement on Form S-1
(Reg. No. 333-212892)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned hereby requests acceleration of the effective date of the above-referenced Registration Statement to 4:00 P.M., Washington, D.C. time, on Friday, August 12, 2016, or as soon thereafter as is practicable. Please call David Ficksman at (310) 789-1290 to confirm the effectiveness.
In making this request, Bone Biologics Corporation (the “Company”) acknowledges that:
● should the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, that act will not foreclose the Commission from taking any action with respect to the filing;
● the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosures in the Registration Statement; and
● the Company may not assert staff comments or the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The Company also understands that this request for acceleration will be considered a confirmation of its awareness of its obligations under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the registered securities.
Very
truly yours,
/s/
DEINA WALSH
Show Raw Text
CORRESP
1
filename1.htm
BONE
BIOLOGICS CORPORATION
321 cOLUMBUS aVENUE
BOSTON, MASSACHUSETTS 02116
August
8, 2016
VIA
EDGAR
Securities
and Exchange Commission
100
F Street, N.E.
Washington,
D.C. 20549-6010
Re:
Bone
Biologics Corporation; Registration Statement on Form S-1
(Reg.
No. 333-212892)
Ladies
and Gentlemen:
In
accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned hereby requests acceleration of the effective
date of the above-referenced Registration Statement to 4:00 P.M., Washington, D.C. time, on Friday, August 12, 2016, or as soon
thereafter as is practicable. Please call David Ficksman at (310) 789-1290 to confirm the effectiveness.
In
making this request, Bone Biologics Corporation (the “Company”) acknowledges that:
●
should
the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, that act
will not foreclose the Commission from taking any action with respect to the filing;
●
the
action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective
does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosures in the Registration
Statement; and
●
the
Company may not assert staff comments or the declaration of effectiveness as a defense in any proceeding initiated by the
Commission or any person under the federal securities laws of the United States.
The
Company also understands that this request for acceleration will be considered a confirmation of its awareness of its obligations
under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the
registered securities.
Very
truly yours,
/s/
DEINA WALSH
Deina
Walsh
Chief
Financial Officer
cc:
David
L. Ficksman
Stephen
LaNeve